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Background {#s1}
==========

Age-related macular degeneration (AMD) has become a major cause of irreversible visual impairments in elderly people around the world, casting a heavy socio-economic burden on eye care [@pone.0108196-Bressler1], [@pone.0108196-Jager1], [@pone.0108196-Lim1]. AMD can be classified into the early and late stages. Patients with early AMD are usually asymptomatic, while severe vision loss frequently occurs in its late stage. Late AMD can be further categorized into two main subtypes: neovascular AMD (nAMD) and geographic atrophy (GA) [@pone.0108196-Lim1]. The estimated prevalence is 6.8% for early AMD and 1.5% for late AMD in Caucasians over the age of 40 years [@pone.0108196-Lim1]. It is estimated that 5% of early AMD patients will progress to late AMD over a 5-year period, increasing to nearly 15% over a 15-year period [@pone.0108196-Cheung1], [@pone.0108196-Mitchell1]. Similar prevalence has been identified in Asians but not in the black population [@pone.0108196-Kawasaki1], [@pone.0108196-Friedman1].

The pathogenesis of AMD is complicated with multiple risk factors, including age, ocular dysfunctions, systemic diseases, diet, smoking, genetic, and environmental factors [@pone.0108196-Chakravarthy1]. As a modifiable personal factor, whether diabetes play a role in the development and progression of AMD has been vigorously studied. While several reports presented positive correlations between diabetes and AMD [@pone.0108196-Topouzis1], [@pone.0108196-Borger1], [@pone.0108196-Karesvuo1], [@pone.0108196-McGwin1], [@pone.0108196-Nitsch1], [@pone.0108196-Vaicaitiene1], some other reports showed no such effect [@pone.0108196-FraserBell1], [@pone.0108196-Xu1]. Even inversed relationship has been reported [@pone.0108196-Clemons1]. To gain a clear insight into the relationship between AMD and diabetes, we conducted a meta-analysis to assess whether diabetes is a risk factor for AMD.

Methods {#s2}
=======

Eligibility Criteria for Considering Studies for This Review {#s2a}
------------------------------------------------------------

Included studies were: (1) studies evaluating diabetes as an individual risk factor for AMD; (2) prospective or retrospective cohort study, or study of cross-sectional or case-control design; (3) studies using predefined criteria and procedures for diabetes diagnosis and AMD grading; and (4) relative risks (RRs), hazard ratios (HRs), and odds ratio (ORs) have been reported, or data provided that enabled calculations of these outcomes. Case reports, reviews, abstracts, conference proceedings, editorials, reports with incomplete data, and non-English articles were excluded. For serial publications from the same research team using overlapped subjects, we included those: (1) with the latest follow-up information; and (2) providing adjusted RRs, HRs, or ORs with 95% CIs. To come up with a more precise insight into whether diabetes is an independent risk factor for AMD, only studies investigating diabetes as the main exposure, or provides adjusted RRs, HRs, or ORs with 95% CIs were included. This study was approved and reviewed by the institutional ethics committee of The First Affiliated Hospital of Nanjing Medical University and adhered to the tenets of the Declaration of Helsinki.

Search Methods for Identifying Studies {#s2b}
--------------------------------------

We searched MEDLINE, EMBASE, and the Cochrane Library for all relevant articles starting from year 1946 to March 18, 2014. We followed the Cochrane Handbook for Systematic Reviews of Interventions [@pone.0108196-XX1] and Meta-analysis of Observational Studies in Epidemiology (MOOSE) guideline [@pone.0108196-Stroup1] in designing and reporting the current study. Our search strategies were detailed in **[Appendix S1](#pone.0108196.s005){ref-type="supplementary-material"}**. No language filters was applied. Additional studies were identified from reference lists of the retrieved reports. Retrieved records and eligibility status were managed using EndNote X5 software (<http://endnote.com/>).

Study Selection {#s2c}
---------------

Two investigators (X.C. and S.S.R.) independently screened all retrieved citations based on title, abstract, and complete document if necessary. All relevant full-text articles were obtained and reviewed to determine the eligibility of each study. Disagreements were resolved via consensus with a senior reviewer (C.Z.).

Data Collection and Risk of Bias Assessment {#s2d}
-------------------------------------------

The two reviewers (X.C. and S.S.R.) extracted outcomes from each study separately with a customized datasheet. Data obtained included: first author, year of publication, title of the study (if any), duration of the study, country or region, races, study design, sample size, estimated ORs, RRs, or HRs, adjusted factors in multiple regression analysis, and clinical examinations and diagnostic criteria for AMD and diabetes. We used the Newcastle Ottawa Scale (NOS, accessed via <http://www.ncbi.nlm.nih.gov/books/NBK35156/>) [@pone.0108196-Yuan1] and the criteria recommended by Agency for Healthcare Research and Quality (AHRQ, accessed via <http://www.ncbi.nlm.nih.gov/books/NBK35156/>) [@pone.0108196-Rostom1] to evaluate the risk of biases for prospective cohorts or case-control studies, and cross-sectional studies, respectively. All data from these two reviewers were compared. Agreement among the reviewers was sought after completion of grading.

Data Synthesis and Analysis {#s2e}
---------------------------

We assessed the association between diabetes and AMD by combining ORs from case-control and cross-sectional studies, and RRs or HRs from cohort studies. Heterogeneity between studies were tested by Cochran\'s Q statistic, and evaluated by the proportion of variation attributable to among-study heterogeneity, *I^2^*. Heterogeneity among studies was considered no, low, moderate, and high when *I^2^* equals to 0% to 24%, 25% to 49%, 50% to 74%, and more than 75%, respectively. If *p* for Q\<0.1 or *I^2^*\>50%, a random-effects model (the DerSimonian and Laird method) was used [@pone.0108196-DerSimonian1], otherwise we used a fixed-effects model(the Mantel-Haenszel method) [@pone.0108196-Kuritz1]. Subgroup analysis was conducted by the study designs, AMD stages and clinical subtypes, and ethnic groups. The Asians were further divided into subgroups, including the East Asians (Japan, China, Taiwan, and Korea), Southeast Asians (Singapore), West Asians (Israel, Iran, and Turkey), and South Asians (Nepal, and India). As to the subgroup analysis concerning different AMD stages, we applied the widely accepted clinical classification system as described by the Age-Related Eye Disease Study Research Group [@pone.0108196-Davis1], [@pone.0108196-Ferris1]. Briefly, early AMD was defined by the appearance of drusen and pigmentary alterations within 2 disc diameters of the fovea. Late AMD was featured by the presence of large drusen (soft and/or indistinct) together with pigmentary abnormalities, or can be generally recognized as nAMD and/or GA. Moreover, sensitivity analysis was conducted to affirm the estimated association by removing studies with poor quality or prone to introducing biases. Publication bias and small-study effects were assessed with funnel plots [@pone.0108196-Begg1] and Egger\'s test [@pone.0108196-Egger1]. All analyses were conducted with Review Manager version 5.2 (Cochrane Collaboration, Oxford, UK; <http://ims.cochrane.org/revman>) and STATA software (version 12.0; StataCorp LP, College Station, TX). Alpha was set to 0.05 for two-sided test.

Results {#s3}
=======

Literature {#s3a}
----------

A total of 3205 records were yielded from digital search and manual screen of reference list. Thirty-eight articles, published from 1986 to 2013, were included for the systematic review. Workflow of literature screen and review was shown in [**Figure 1**](#pone-0108196-g001){ref-type="fig"}. In addition, to provide a better understanding in diabetes as an independent risk factor for AMD, fourteen studies that presented diabetes as a covariate and provided ORs/RRs/HRs from baseline data without any adjustment were excluded, involving 12 cross-sectional [@pone.0108196-Karesvuo1], [@pone.0108196-FraserBell1], [@pone.0108196-Clemons1], [@pone.0108196-Wong1], [@pone.0108196-Jeganathan1], [@pone.0108196-Baker1], [@pone.0108196-Pokharel1], [@pone.0108196-Hu1], [@pone.0108196-Weiner1], [@pone.0108196-Cheung2], [@pone.0108196-Yang1], [@pone.0108196-LaTorre1] and 2 case-control studies [@pone.0108196-Mattes1], [@pone.0108196-Vine1]. The 24 articles included 1858350 participants in 27 independent study populations, comprising 7 cohort studies [@pone.0108196-Hahn1], [@pone.0108196-Shalev1], [@pone.0108196-Leske1], [@pone.0108196-Tomany1], [@pone.0108196-Yasuda1], 9 cross-sectional studies [@pone.0108196-Topouzis1], [@pone.0108196-Vaicaitiene1], [@pone.0108196-Xu1], [@pone.0108196-Delcourt1], [@pone.0108196-Duan1], [@pone.0108196-Klein1], [@pone.0108196-Choi1], [@pone.0108196-GemmyCheung1], and 11 case-control studies [@pone.0108196-McGwin1], [@pone.0108196-Nitsch1], [@pone.0108196-LaTorre1], [@pone.0108196-Blumenkranz1], [@pone.0108196-Ross1], [@pone.0108196-Monnier1], [@pone.0108196-Alexander1], [@pone.0108196-Kim1], [@pone.0108196-Lin1], [@pone.0108196-Cackett1], [@pone.0108196-Sogut1]. Among the 27 study populations, 10 were in Asia, 9 in North America (United States), 6 in Europe, 1 in Oceania (Australia), and 1 in South America (Barbados). Most studies used predefined criteria for AMD diagnosis and adopted standard grading system [@pone.0108196-Klein2], [@pone.0108196-Bird1]. Samples sizes varied widely, from less than 50 to over 1.5 million ([**Table 1**](#pone-0108196-t001){ref-type="table"}). Only two of the earliest studies, in 1986 [@pone.0108196-Blumenkranz1] and 1998 [@pone.0108196-Ross1], had sample sizes less than 100. Risk of bias assessments for cohort, cross-sectional, and case-control studies has been performed (**[Tables S1](#pone.0108196.s001){ref-type="supplementary-material"}--[S3](#pone.0108196.s003){ref-type="supplementary-material"}**). Tan et al [@pone.0108196-Tan1] and Tomany et al [@pone.0108196-Tomany1] both involved the Blue Mountain Eye Study cohort, we included latter one in the analysis. The ORs/RRs/HRs with 95% CI and the corresponding adjusted variables for each study were listed in overall AMD, early AMD or late AMD ([**Table 2**](#pone-0108196-t002){ref-type="table"}).

![Flow chart depicting the screening process for inclusion in the meta-analysis.](pone.0108196.g001){#pone-0108196-g001}

10.1371/journal.pone.0108196.t001

###### Characteristics of Included Cohorts.

![](pone.0108196.t001){#pone-0108196-t001-1}

  First Author (Publication Year)                             Study         Study Period                   Region                        Race         Sample Size   Diagnostic Criteria  
  ---------------------------------------------------- ------------------- -------------- ---------------------------------------- ----------------- ------------- --------------------- ---------------
  ***Cohort Studies (Prospective & Retrospective)***                                                                                                                                     
  Tomany et al (2004)                                         BDES           1993--1995                      US                        Caucasian         3562              I & W             PGL & S
                                                              BMES           1997--1999                  Australia                     Caucasian         2330              I & W             PGL & S
                                                               RS            1997--1999                 Netherlands                    Caucasian         3631              I & W             PGL & S
  Leske et al (2006)                                        BISED II         1987--1992                   Barbados                       Mixed           2793                W                M & S
  Yasuda et al (2009)                                    Hisayama Study         2007                       Japan                      East Asian         1401              I & W             M & PGL
  Shalev et al (2011)                                          MHS           1998--2007                    Israel                     West Asian        108973             ICD9                 M
  Hahn et al (2013)                                            NA            1995--2005                      US                        Caucasian         16510             ICD9               ICD9
  ***Cross-sectional Studies***                                                                                                                                                          
  Delcourt et al (2001)                                       POLA           1995--1997                    France                      Caucasian         2584              I & W            Interview
  Vaičaitienė et al (2003)                                     NA            1995--1997                  Lithuania                     Caucasian          438               NA                 NA
  Duan et al (2007)                                            NA            2000--2001                      US                        Caucasian        1519086            ICD9               ICD9
  Klein et al (2007)                                          WHISE          1993--2002                      US                        Caucasian         4288                W                  M
  Topouzis et al (2009)                                   EUREYE study       2000--2003    Europe[¶](#nt101){ref-type="table-fn"}      Caucasian         4722                I                  S
  Xu et al (2009)                                       Beijing Eye Study       2006                       China                      East Asian         2960                W               PGL & S
  Choi et al (2011)                                            NA            2006--2008                    Korea                      East Asian         3008                W               M & PGL
  Cheung et al (2013)                                         SIES           2007--2009                  Singapore                  Southeast Asian      3337                W               PGL & S
                                                              CIEMS          2006--2008                    India                      South Asian        3422                W               PGL & S
  ***Case-control Studies***                                                                                                                                                             
  Blumenkranz et al (1986)                                     NA                NA                          US                        Caucasian          49                NA                 PGL
  Ross et al (1998)                                            NA                NA                          US                        Caucasian          94        Detailed in paper.          M
  McGwin et al (2003)                                          NA            1997--2001                      US                        Caucasian         6050              ICD9               ICD9
  Moeini et al (2005)                                          NA               2001                        Iran                      West Asian          130               NA                 PGL
  Alexander et al (2007)                                       NA            2001--2003                      US                        Caucasian         62179             ICD9               ICD9
  Kim et al (2008)                                             NA            1998--2003                      US                        Caucasian          204                W            Questionnaire
  Lin et al (2008)                                             NA            2002--2006                    Taiwan                     East Asian          280                I                 NA
  Nitsch et al (2008)                                         GPRD           1987--2002                      UK                        Caucasian        104176       Readcodes & OXMIS          M
  Cackett et al (2011)                                         NA            2007--2008                  Singapore                  Southeast Asian      1617                W            Questionnaire
  Sogut et al (2013)                                           NA                NA                        Turkey                     West Asian          280                W                 ADA
  Torre et al (2013)                                           NA               2011                       Italy                       Caucasian          246               NA            Questionnaire

Europe: Estonia, France, Greece, Italy, Norway, Spain, UK;

Abbreviation: BDES: Beaver Dam Eye Study; BMES: Blue Mountains Eye Study; RS: Rotterdam Study; BISED II: Barbados Incidence Study of Eye Diseases; MHS: Maccabi Healthcare Services; NA: not available; POLA: Pathologies Oculaires Liées àl\'Age Study; WHISE: Women\'s Health Initiative Sight Examination; SIES: Singapore Indian Eye Study; CIEMS: Central India Eye and Medical Study; GPRD: General Practice Research Database; AMD: Age Related Macular Degeneration; &: represents a combination of two diagnostic methods; I: International Classification and Grading System for AMD; W: Wisconsin Age-Related Maculopathy Grading System; ICD9: International Classification of Diseases with Clinical Modifications, Ninth Revision; PGL: Plasma Glucose Level; S: Self-reported diabetic history or medications; M: Medical recorded diabetic history or medications; ADA: American Diabetes Association diagnostic criteria.

10.1371/journal.pone.0108196.t002

###### Detailed Analytical Information for Included Cohorts.

![](pone.0108196.t002){#pone-0108196-t002-2}

  First Author(Publication Year)                        OR/RR/HR[Δ](#nt103){ref-type="table-fn"} \[95% CI\]   Adjusted Variables                                                                      
  ---------------------------------------------------- ----------------------------------------------------- --------------------- ---------------------- --------------------- --------------------- ---------------------------------------------------
  ***Cohort Studies (Prospective & Retrospective)***                                                                                                                                                  
  Tomany (2004)                                                                 ---                           0.67 \[0.24, 1.86\]   2.05 \[0.84, 4.99\]    1.21 \[0.62, 2.36\]   1.21 \[0.62, 2.36\]                       Age, Sex
  *BDES*                                                                        ---                                   ---           0.79 \[0.10, 6.31\]            ---                   ---                               Age, Sex
  *BMES*                                                                        ---                                   ---           8.31 \[2.34, 29.50\]           ---                   ---                               Age, Sex
  *RS*                                                                          ---                                   ---           0.79 \[0.10, 6.19\]            ---                   ---                               Age, Sex
  Leske (2006)                                                          0.88 \[0.60, 1.30\]                           ---                   ---            2.70 \[1.00, 7.30\]   1.02 \[0.71, 1.47\]                          Age
  Yasuda (2009)                                                         0.70 \[0.37, 1.31\]                           ---                   ---            0.69 \[0.16, 2.95\]   0.69 \[0.39, 1.24\]   Multiple Factors[\#](#nt104){ref-type="table-fn"}
  Shalev (2011)                                                                 ---                                   ---                   ---                    ---           1.18 \[1.01, 1.38\]                   Mutually adjusted
  Hahn (2013)                                                                   ---                           1.11 \[0.97, 1.27\]   1.03 \[0.97, 1.09\]    1.04 \[0.99, 1.10\]   1.04 \[0.99, 1.10\]   Multiple Factors[\*](#nt105){ref-type="table-fn"}
  ***Cross-sectional Studies***                                                                                                                                                                       
  Delcourt (2001)                                                               ---                                   ---                   ---            1.22 \[0.45, 3.29\]   1.22 \[0.45, 3.29\]                       Age, Sex
  Vaičaitienė (2003)                                                            ---                                   ---                   ---                    ---           4.61 \[2.45, 8.67\]                       Age, Sex
  Duan (2007)                                                                   ---                           1.48 \[1.44, 1.51\]           ---            1.48 \[1.44, 1.51\]   1.18 \[1.16, 1.19\]                    Age, Sex, Race
  Klein (2007)                                                          0.87 \[0.67, 1.12\]                   2.49 \[1.17, 5.31\]   2.28 \[0.63, 8.28\]    2.43 \[1.26, 4.70\]   0.94 \[0.74, 1.20\]                          Age
  Topouzis (2009)                                                       0.98 \[0.83, 1.17\]                   1.81 \[1.10, 2.98\]   1.06 \[0.28, 4.04\]    1.38 \[0.90, 2.12\]   1.01 \[0.85, 1.19\]   Multiple Factors[‡](#nt106){ref-type="table-fn"}
  Xu (2009)                                                             1.30 \[0.69, 2.43\]                           ---                   ---            1.13 \[0.14, 9.40\]   1.28 \[0.70, 2.34\]                         None
  Choi (2011)                                                           1.87 \[1.07, 3.28\]                           ---                   ---                    ---           1.87 \[1.07, 3.28\]   Multiple Factors[†](#nt107){ref-type="table-fn"}
  Cheung (2013)                                                                                                                                                                                       
  *SIES*                                                                0.93 \[0.68, 1.28\]                           ---                   ---                    ---           0.93 \[0.68, 1.28\]                       Age, Sex
  *CIEMS*                                                               1.14 \[0.47, 2.77\]                           ---                   ---                    ---           1.14 \[0.47, 2.77\]                       Age, Sex
  ***Case-control Studies***                                                                                                                                                                          
  Blumenkranz (1986)                                                            ---                                   ---                   ---            0.53 \[0.06, 4.71\]   0.53 \[0.06, 4.71\]                     Use siblings
  Ross (1998)                                                                   ---                                   ---                   ---                    ---           1.09 \[0.21, 5.59\]                          Age
  McGwin Jr (2003)                                                              ---                                   ---                   ---                    ---           1.78 \[1.43, 2.20\]                       Age, Sex
  Moeini (2005)                                                                 ---                                   ---                   ---                    ---           1.29 \[0.52, 3.21\]                Age, Sex, Risk factors
  Alexander (2007)                                                              ---                           1.16 \[1.11, 1.21\]           ---            1.16 \[1.11, 1.21\]   1.16 \[1.11, 1.21\]            Age, Sex, Race, Database length
  Kim (2008)                                                                    ---                           0.61 \[0.27, 1.39\]           ---            0.61 \[0.27, 1.39\]   0.61 \[0.27, 1.39\]                     Use siblings
  Lin (2008)                                                                    ---                           1.20 \[0.44, 3.26\]   0.97 \[0.36, 2.63\]    1.07 \[0.45, 2.57\]   1.07 \[0.45, 2.57\]                       Age, Sex
  Nitsch (2008)                                                                 ---                                   ---                   ---                    ---           1.36 \[1.29, 1.43\]         Age, Sex, Practice, Consultation Rate
  Cackett (2011)                                                                ---                           0.92 \[0.50, 1.70\]           ---            0.92 \[0.50, 1.70\]   0.92 \[0.50, 1.70\]                       Age, Sex
  Sogut (2013)                                                                  ---                                   ---                   ---            1.68 \[0.76, 3.69\]   1.68 \[0.76, 3.69\]                       Age, Sex
  Torre (2013)                                                                  ---                                   ---                   ---                    ---           0.80 \[0.08, 8.07\]                   Age, Sex, Smoking

OR is for cross-sectional and case-control studies, RR is for prospective cohort studies, HR is for retrospective cohort studies;

Age, Sex, Smoking habit, White blood cells;

\*Age, Sex, Race, History of hypertension, Atherosclerosis, Stroke, Coronary heart disease, Hyperlipidemia, Charlson index;

Age, Sex, Smoking, Education, BMI, Alcohol consumption, Cardiovascular disease, Aspirin use, Systolic blood pressure, Alpha-tocopherol ratio, Vitamin C, Lutein;

Age, Sex, Current smoking, Obesity, Hypertension.

Abbreviations: OR: odds ratio; RR: risk ratio; HR: hazard ratio; CI: confidence interval; AMD: Age-related macular degeneration; nAMD: neovascular AMD; GA: geographic atrophy; WBC: white blood cell.

Meta-Analysis {#s3b}
-------------

The effects of diabetes on the risk of AMD in all these studies were found to be essentially consistent ([**Figure 2**](#pone-0108196-g002){ref-type="fig"} **and** [**Table 3**](#pone-0108196-t003){ref-type="table"}). According to the meta-analysis of 7 cohort studies, diabetes was associated with AMD (OR, 1.05; 95% CI, 1.00--1.11). Subgroup analysis based on AMD stages revealed diabetes as a marginal risk factor for late AMD (OR, 1.05; 95% CI, 0.99--1.10), but not for its early form (OR, 0.83; 95% CI, 0.60--1.15). Subgroup analysis by AMD subtypes showed that the pooled OR of diabetes for risk of nAMD was 1.10 (95% CI, 0.96--1.26), for risk of GA was 1.63 (95% CI, 0.51--5.21). In the 9 cross-sectional study populations, diabetes was found increasing AMD risk (OR, 1.21; 95% CI, 1.00--1.45). Subgroup analysis confirmed this effect for late AMD (OR, 1.48; 95% CI, 1.44--1.51), and nAMD (OR, 1.48; 95% CI, 1.44--1.51), but not for early AMD (OR, 0.99; 95% CI, 0.88--1.12) or GA (OR, 1.58; 95% CI, 0.63--3.99). The results kept consistent in the analysis of 11 case-control studies. The pooled OR of diabetes for AMD was 1.29 (95% CI, 1.13--1.49). The pooled OR was 1.16 (95% CI, 1.11--1.21) for late AMD, and 1.15 (95% CI, 1.11--1.21) for nAMD. To reduce the methodological heterogeneity and the potential effect led by other risk factors, we also conducted meta-analysis solely using multivariate-adjusted outcomes. Only 3 cohort studies and 2 cross-sectional were included, and the results varied from the overall data, which was probably due to the limited number of included studies. However, in both groups, diabetes was found as a marginal risk factor for nAMD in cross-sectional studies (OR, 1.04; 95% CI, 0.99--1.10) and a solid risk factor for late AMD in cohort studies (OR, 1.81; 95% CI, 1.10--2.98). No association between diabetes and early AMD or GA was found in both groups ([**Table 4**](#pone-0108196-t004){ref-type="table"}). Subgroup analyses by ethnic group were further performed. The associations of diabetes and overall and early AMD were similar between the Asian and Caucasian populations ([**Table 5**](#pone-0108196-t005){ref-type="table"}), while associations between diabetes and all subtypes of late AMD were suggested only for the Caucasian group, but not for the overall Asian population or any of its subgroups. No indication of any obvious asymmetry was observed according to the shapes of Begg\'s funnel plots and Egger\'s test for all groups as detailed in [**Tables 3**](#pone-0108196-t003){ref-type="table"} **--** [**5**](#pone-0108196-t005){ref-type="table"}.

![Effects of diabetes on AMD risks.\
Graphs showing the effects of diabetes on the risk of Age-related Macular Degenerations in longitudinal cohort studies (A), cross-sectional studies (B), and case-control studies (C). IV: inverse variance, CI: confidence interval.](pone.0108196.g002){#pone-0108196-g002}
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###### Analysis of Diabetes as a Risk Factor for AMD in Different AMD Types.

![](pone.0108196.t003){#pone-0108196-t003-3}

  Study Design                     No. of Cohorts   Sample Size                     Overall Effect                      Heterogeneity   *Egger*\'*s Test*               
  ------------------------------- ---------------- ------------- ----------------------------------------------------- --------------- ------------------- ---- ------- -------
  ***Cohort Studies***                                                                                                                                                  
  AMD                                    7            139200                      1.05 \[1.00, 1.11\]                       2.09              0.037         8    0.361   0.961
  Early AMD                              2             4194                       0.83 \[0.60, 1.15\]                       1.12              0.261         0    0.529    NA
  Late AMD                               6             30227                      1.05 \[0.99, 1.10\]                       1.70              0.088         25   0.260   0.504
  nAMD                                   4             26033                      1.10 \[0.96, 1.26\]                       1.40              0.160         0    0.335    NA
  GA                                     4             26033      1.63 \[0.51, 5.21\][†](#nt110){ref-type="table-fn"}       0.83              0.407         72   0.014   0.523
  ***Cross-sectional Studies***                                                                                                                                         
  AMD                                    9            1543845     1.21 \[1.00, 1.45\][†](#nt110){ref-type="table-fn"}       2.00              0.045         73   0.000   0.813
  Early AMD                              6             21737                      0.99 \[0.88, 1.12\]                       0.15              0.883         28   0.224   0.205
  Late AMD                               5            1533640                     1.48 \[1.44, 1.51\]                       32.20             0.000         0    0.642   0.774
  nAMD                                   3            1528096                     1.48 \[1.44, 1.51\]                       32.23             0.000         20   0.287   0.154
  GA                                     2             9010                       1.58 \[0.63, 3.99\]                       0.97              0.333         0    0.419    NA
  ***Case-control Studies***                                                                                                                                            
  AMD                                    11           175305      1.29 \[1.13, 1.49\][†](#nt110){ref-type="table-fn"}       3.67              0.000         73   0.000   0.976
  Late AMD                               6             64609                      1.16 \[1.11, 1.21\]                       6.65              0.000         0    0.520   0.334
  nAMD                                   4             62179                      1.15 \[1.11, 1.21\]                       6.55              0.000         0    0.416   0.257
  GA                                     1              280                       0.97 \[0.36, 2.63\]                       0.06              0.954         NA    NA      NA

\* OR is for cross-sectional and case-control studies, RR is for cohort studies.

Studies using random effect model.

Abbreviations: OR: odds ratio; RR: risk ratio; CI: confidence interval; AMD: age related macular degeneration; nAMD: neovascular AMD; GA: geographic atrophy; NA: not available.

10.1371/journal.pone.0108196.t004

###### Analysis of Diabetes as a Risk Factor for AMD in Different AMD Types with Multivariate-adjusted ORs/RRs/HRs.
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  Study Design                     No. of Cohorts   Sample Size                     Overall Effect                      Heterogeneity   Egger\'s Test               
  ------------------------------- ---------------- ------------- ----------------------------------------------------- --------------- --------------- ---- ------- -------
  ***Cohort Studies***                                                                                                                                              
  AMD                                    3            126884      1.07 \[0.93, 1.22\][†](#nt113){ref-type="table-fn"}       0.96            0.339       52   0.125   0.904
  Early AMD                              1             1401                       0.70 \[0.37, 1.31\]                       1.12            0.262       NA    NA      NA
  Late AMD                               2             17911                      1.04 \[0.99, 1.10\]                       1.56            0.118       0    0.574    NA
  nAMD                                   1             16510                      1.11 \[0.97, 1.27\]                       1.52            0.129       NA    NA      NA
  GA                                     1             16510                      1.03 \[0.97, 1.09\]                       0.94            0.349       NA    NA      NA
  ***Cross-sectional Studies***                                                                                                                                     
  AMD                                    2             7730       1.29 \[0.71, 2.35\][†](#nt113){ref-type="table-fn"}       0.85            0.397       77   0.038    NA
  Early AMD                              2             7730       1.28 \[0.69, 2.39\][†](#nt113){ref-type="table-fn"}       0.78            0.640       78   0.031    NA
  Late AMD                               1             4722                       1.38 \[0.90, 2.12\]                       1.46            0.145       NA    NA      NA
  nAMD                                   1             4722                       1.81 \[1.10, 2.98\]                       2.34            0.020       NA    NA      NA
  GA                                     1             4722                       1.06 \[0.28, 4.04\]                       0.09            0.928       NA    NA      NA

\* OR is for cross-sectional and case-control studies, RR is for cohort studies.

Studies using random effect model.

Abbreviations: OR: odds ratio; RR: risk ratio; CI: confidence interval; AMD: age related macular degeneration; nAMD: neovascular AMD; GA: geographic atrophy; NA: not available.

10.1371/journal.pone.0108196.t005

###### Analysis of Diabetes as a Risk Factor for AMD in Different Ethnic Groups.

![](pone.0108196.t005){#pone-0108196-t005-5}

  Ethnic Group                No. of cohorts   Sample Size                     Overall Effect                      Heterogeneity   *Egger*\'*s Test*                 
  -------------------------- ---------------- ------------- ----------------------------------------------------- --------------- ------------------- ---- --------- -------
  ***AMD***                                                                                                                                                          
  Caucasian                         16           1730149     1.20 \[1.12, 1.29\][†](#nt116){ref-type="table-fn"}       4.86              0.000         84    0.000    0.733
  Asian                             10           125408                      1.14 \[1.01, 1.29\]                       2.11              0.035         2     0.423    0.978
  * East Asian*                     4             7649                       1.18 \[0.86, 1.61\]                       1.03              0.301         49    0.115    0.856
  * West Asian*                     3            109383                      1.20 \[1.03, 1.39\]                       2.35              0.019         0     0.688    0.385
  * Southeast Asian*                2             4954                       0.93 \[0.70, 1.23\]                       0.50              0.616         0     0.973     NA
  * South Asian*                    1             3422                       1.14 \[0.47, 2.77\]                       0.29              0.771         NA     NA       NA
  Total                             27           1858350     1.18 \[1.11, 1.26\][†](#nt116){ref-type="table-fn"}       5.11              0.000         74    0.000    0.909
  ***Early AMD***                                                                                                                                                    
  Caucasian                         2             9010                       0.95 \[0.82, 1.09\]                       0.77              0.442         0     0.422     NA
  Asian                             5             14128                      1.06 \[0.85, 1.34\]                       0.54              0.588         40    0.152    0.626
  * East Asian*                     3             7369       1.21 \[0.68, 2.14\][†](#nt116){ref-type="table-fn"}       0.65              0.517         62    0.070    0.385
  * Southeast Asian*                1             3337                       0.93 \[0.68, 1.28\]                       0.43              0.667         NA     NA       NA
  * South Asian*                    1             3422                       1.14 \[0.47, 2.77\]                       0.29              0.771         NA     NA       NA
  Total                             8             25931                      0.97 \[0.86, 1.09\]                       0.53              0.595         16    0.303    0.478
  ***Late AMD***                                                                                                                                                     
  Caucasian                         11           1619145     1.25 \[1.05, 1.49\][†](#nt116){ref-type="table-fn"}       2.50              0.013         96    0.000    0.479
  Asian                             5             6538                       1.09 \[0.73, 1.63\]                       0.44              0.663         0     0.770    0.882
  * East Asian*                     3             4641                       0.97 \[0.48, 1.97\]                       0.07              0.941         0     0.865    0.800
  * Southeast Asian*                1             1617                       0.92 \[0.50, 1.70\]                       0.26              0.795         NA     NA       NA
  * West Asian*                     1              280                       1.68 \[0.76, 3.69\]                       1.28              0.200         NA     NA       NA
  Total                             17           1628476     1.25 \[1.07, 1.46\][†](#nt116){ref-type="table-fn"}       2.74              0.006         92    0.000    0.454
  ***Neovascular AMD***                                                                                                                                              
  Caucasian                         9            1616512     1.29 \[1.09, 1.54\][†](#nt116){ref-type="table-fn"}       2.92              0.003         94   \<0.001   0.524
  Asian                             2             1897                       0.99 \[0.59, 1.67\]                       0.04              0.970         0     0.662     NA
  * East Asian*                     1              280                       1.20 \[0.44, 3.26\]                       0.35              0.724         NA     NA       NA
  * Southeast Asian*                1             1617                       0.92 \[0.50, 1.70\]                       0.26              0.795         NA     NA       NA
  Total                             11           1618409     1.27 \[1.07, 1.50\][†](#nt116){ref-type="table-fn"}       2.81              0.005         93   \<0.001   0.429
  ***Geographic Atrophy***                                                                                                                                           
  Caucasian                         6             24408                      1.97 \[1.07, 3.64\]                       2.17              0.030         35    0.172    0.178
  Asian                             1              280                       0.97 \[0.36, 2.63\]                       0.06              0.954         NA     NA       NA
  *East Asian*                      1              280                       0.97 \[0.36, 2.63\]                       0.06              0.954         NA     NA       NA
  Total                             7             24688                      1.62 \[0.96, 2.74\]                       1.82              0.069         34    0.166    0.687

\* OR is for cross-sectional and case-control studies, RR is for prospective cohort studies.

Studies using random effect model.

Abbreviations: OR: odds ratio; RR: relative risk; CI: confidence interval; AMD: age related macular degeneration.

Risk of Bias Assessment and Sensitivity Analysis {#s3c}
------------------------------------------------

In our assessment, we found most studies have a robust design and reported in a clear manner, thus have lower risks in introducing bias (**[Tables S1](#pone.0108196.s001){ref-type="supplementary-material"}--[S3](#pone.0108196.s003){ref-type="supplementary-material"}**). However, we did identify one cross-sectional study which had relative higher risk to introduce biases when used to evaluate risk-modifying effect of diabetes for AMD [@pone.0108196-Vaicaitiene1] (**[Tables S2](#pone.0108196.s002){ref-type="supplementary-material"}**), thus were subjected to sensitivity analysis. In sensitivity analysis, we sequentially omitted one study at a time and removed studies of higher risk of introducing bias to affirm the associations. Sensitivity analyses revealed that the study conducted by Alexander et al [@pone.0108196-Alexander1] contributed to the heterogeneity in the subgroup analysis of case-control studies, but did not alter the results in each subgroup. When removing the studies conducted by Shalev et al and Hahn et al in the subgroup analysis of cohort studies, respectively, although the *p* values for diabetes and AMD became insignificant, the direction of ORs was kept and associations of marginal significance were revealed (removing study by Shalev et al: OR, 1.04; 95% CI, 0.99--1.10; Hahn et al: OR, 1.12; 95% CI, 0.98--1.29). Similar findings were revealed by subgroup analyses involving cross-sectional and case-control studies. In the analysis of cross-sectional studies, the removal of studies by Vaičaitienė et al [@pone.0108196-Vaicaitiene1], Duan et al [@pone.0108196-Duan1], Xu et al [@pone.0108196-Xu1], and Choi et al [@pone.0108196-Choi1] would also lead to borderline results (removing study by Vaičaitienė et al: OR, 1.10; 95% CI, 0.98--1.23; Duan et al: OR, 1.30; 95% CI, 0.97--1.73; Xu et al: OR, 1.21; 95% CI, 0.99--1.47; Choi et al: OR, 1.16; 95% CI, 0.96--1.41). In addition, in the subgroup analysis of case-control studies, an association of borderline significance between diabetes and AMD (OR, 1.23; 95% CI, 0.97--1.56) was presented if the study by Nitsch et al [@pone.0108196-Nitsch1] was excluded.

Discussion {#s4}
==========

Diabetes is a major concern in ophthalmic care. Whether it contributes to the prevalence of AMD has been an unsolved dilemma targeted by a large number of studies. However, obvious inconsistencies between studies, including a few large cohorts, suggest the necessity to conduct an exhaustive review and quantitative analysis on all the evidences to determine its effect. In the present systemic review and meta-analysis, we reviewed 3205 published reports and completed analysis on 1858350 participants of 27 study populations from 24 original studies. We found that diabetes is a risk factor for AMD, especially for nAMD. To our knowledge, this is the first meta-analysis addressing the topic for AMD and all its subtypes, and by using data from a comprehensive collection of prospective and retrospective cohort, cross-sectional, and case-control studies.

Clinically, AMD can be classified based on drusen features and retinal pigment epithelial abnormalities, we found most included studies follow the Wisconsin Age-related Maculopathy Grading Scheme, according to 4 levels: level 1 (no AMD), level 2 and 3 (early AMD), and level 4 (late AMD) [@pone.0108196-Klein2], [@pone.0108196-XX2]. The contribution of diabetes to early AMD is inconsistent in studies. Diabetic patients have increased occurrence of early AMD in a cross-sectional study of a Korean cohort of 3008 adults [@pone.0108196-Choi1]. No similar association has been observed in other studies. An inverse relationship is observed in the Age-Related Eye Disease Study (AREDS) [@pone.0108196-Clemons1]. In the Beaver Dam Eye Study (BDES), diabetes was found to be a protective factor for incident reticular drusen based on a 15-year cumulative incidence [@pone.0108196-Klein3]. In this meta-analysis, no clear association was detected between diabetes and early AMD based on 16 relevant cohorts.

The associations of diabetes with late AMD are also inconsistent among previous reports. According to analysis from 5 cross-sectional and 6 case-control studies, diabetes is significantly correlated with late AMD, especially with nAMD, but not for GA. Temporal relationships revealed by 7 cohort studies further supports diabetes as a potential risk factor for late AMD, only for nAMD but not for GA. However, an association between diabetes and GA was identified in Caucasians. Also, the Blue Mountains Eye Study (BMES) has revealed diabetes as a predictor of incident GA, but not incident nAMD. This is consistent with a cross-sectional baseline report [@pone.0108196-Mitchell2], [@pone.0108196-Smith1], to 5-year [@pone.0108196-Tomany1] and 10-year [@pone.0108196-Tan1] incident reports, providing evidence for a diabetes and GA association.

In the current meta-analysis, we found no obvious ethnic divergence regarding the association between the diabetes and risk of overall AMD and its early form. The results obtained from different Asian groups are consistent in all types of AMD. However, the association between diabetes and late AMD in the Caucasian population differs from that in the Asian population, which is probably due to the large variation of genetic factors among different ethnic groups [@pone.0108196-Klein4], and the differences in dietary habits and lifestyles.

The biological interplay between diabetes and AMD is complicated and has not been fully elucidated. First, diabetic conditions may lead to the accumulation of the highly stable advanced glycation end products (AGEs) in multiple tissues, including the retinal pigment epithelium (RPE) cell layers and photoreceptors [@pone.0108196-Monnier1], [@pone.0108196-Stitt1]. These AGEs would first contribute to the modification of molecules, leading to the activation of NFκB, NFκB nuclear translocation, and up-regulation in the expression of the receptor for AGEs (RAGE) [@pone.0108196-Hammes1]. Further, the up-regulated RAGE, which usually localized to the neuroglia in the inner retina [@pone.0108196-Soulis1], would integrate with AGE, thus leading to high levels of the nondegradable aggregates AGE-RAGE ligands in retina [@pone.0108196-Stitt1]. Therefore, accumulated AGEs would reduce the dosage dependent RAGE-mediated activation of RPE/photoreceptor cells [@pone.0108196-Howes1]. AGEs and RAGE were found in the RPE or both RPE and photoreceptors in the maculas of human donor retina from patients with AMD, but not in normal eyes [@pone.0108196-Hammes1], [@pone.0108196-Howes1], indicating that AGE deposition and RAGE up-regulation in diabetic conditions are implicated in the pathogenesis of AMD.

Second, hyperglycemia and dyslipidemia in diabetic patients will disturb homeostasis of the retina by inducing inflammatory responses in tissue cells, including oxidative stress [@pone.0108196-Zhang1]. Significantly elevated oxidative stress markers and total oxidative stress (TOS), as well as decreased total anti-oxidant capacity (TAC), are found in the serum of AMD patients when compared with age-matched controls free of AMD [@pone.0108196-Totan1], [@pone.0108196-Venza1]. Meanwhile, anti-oxidants and omega-3 fatty acids have been shown to help with the preservation of RPE health and prevent retinal degeneration in animal models [@pone.0108196-Cao1], [@pone.0108196-Tuo1]. Therefore, oxidative stress is recognized as one of the principle pathogenic elements in AMD [@pone.0108196-Ardeljan1]. Oxidative stress may further activate NF-κB regulated inflammatory genes and lead to inflammation, which would in turn generate reactive oxygen species and aggregate oxidative stress. Inflammation disrupts the NF-κB, JUN N-terminal kinase (JNK), and the NADPH oxidase pathways, consequently dysregulations of many inflammatory cytokines and chemokines, involving the tumor necrosis factor (TNF), interleukin-6 (IL-6), IL-1β, C-reactive protein (CRP), CC-chemokine ligand 2 (CCL2), and adipokines [@pone.0108196-Donath1]. These inflammatory activations would lead to the dysfunction and even death of the RPE/photoreceptor cells [@pone.0108196-Zhang1]. Thus, oxidative stress and inflammations in the retina are pre-requites for development of AMD [@pone.0108196-Ardeljan1].

Meanwhile, diabetic microangiopathy shares common pathogenic pathways with AMD. Hyperglycemia and dyslipidemia in diabetic patients will lead to multiple microvascular complications, including diabetic retinopathy (DR). AMD and DR share some common features in pathogenesis and treatment. In a longitudinal study over 10 years, individuals with DR, including both the nonproliferative and proliferative form, were at higher risk for nAMD when compared to diabetic patients without DR or normal controls [@pone.0108196-Hahn1]. Vascular endothelial growth factor (VEGF) seems to play an important role in both DR and AMD, and anti-VEGF treatment are useful for both [@pone.0108196-Ho1], [@pone.0108196-Rofagha1]. Apolipoproteins are also involved. Lower apoAI and higher apoB and apoB/AI levels, biomarkers for diabetic retinopathy [@pone.0108196-Sasongko1], are involved in the pathogenesis of cardiovascular diseases [@pone.0108196-DiAngelantonio1], which is a risk factor for AMD [@pone.0108196-Chakravarthy1], [@pone.0108196-Tan1]. Meanwhile, mitochondrial dysfunctions have been reported to contribute to metabolic disorders as well as AMD [@pone.0108196-Ardeljan1], [@pone.0108196-Turner1], [@pone.0108196-Sorriento1]. All these suggested that hyperglycemia probably affects the function and structure of the retinal pigment epithelium, Bruch membrane, and the choroidal circulation [@pone.0108196-Choi1], thus increase the risk of AMD. Our study indicates a potential relationship between diabetes and late AMD, but further evidences from more epidemiological and biological investigations are required.

To enhance the reliability of our results, we adopted quality assessment tools recommended by the AHRQ and NOS for observational studies. Only studies discussing diabetes as the main exposure or providing adjusted ORs/HRs/RRs were included in the present meta-analysis for a more precise association of diabetes as a relatively independent risk factor for AMD. In addition, for studies reporting duplicated cohorts, only those with the latest follow-up information or provides better adjusted results were included. Subgroup analysis was performed to affirm the association and to explorer the sources of the heterogeneity. Meanwhile, our study entailed some limitations. Data obtained from prospective cohort studies would be more convincing. But the number of prospective cohort studies was quite limited. Retrospective cohort, cross-sectional, and case-control studies were also included in the present study, which may partly help to reflect the association between diabetes and AMD. However, these studies have limitation. Retrospective cohort studies use healthcare databases and have inherent methodological limitations, which may obscure the association between diabetes and AMD [@pone.0108196-Wu1]. Cross-sectional does not establish temporality and case-control studies may introduce selection bias and established temporality [@pone.0108196-Wu1]. Early AMD can be further classified into more specific categories. Herein, we could only judge the relationship between diabetes and early AMD. Other than diabetic status, plenty of other risk factors have been suggested for AMD. Although we have tried to narrow down the influence of other risk factors by selecting studies with adjusted data, some included studies only reported data adjusted for age and sex, and the number of studies providing multivariate-adjusted data was quite limited. With the limited information provided by each individual study, therefore, this present meta-analysis only deals with the relationship between diabetic disease status and risk of AMD, but not the specific type of diabetes, the disease course, and blood glucose levels.

In conclusion, results of this meta-analysis indicate diabetes as a potential risk factor for AMD, especially for its late form. No clear association between diabetes and early AMD is identified. More longitudinal studies are needed to ascertain the association between diabetes and AMD. And biological studies involving the inflammatory pathways might help understand the molecular basis behind this association.
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